trending Market Intelligence /marketintelligence/en/news-insights/trending/cahduJbCre9OdkOh5qJozQ2 content esgSubNav
In This List

Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Aerie Pharmaceuticals' Rhopressa gets US FDA approval to lower eye pressure

The U.S. Food and Drug Administration approved Aerie Pharmaceuticals Inc.'s Rhopressa 0.02% for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The approval was made two months ahead of the scheduled approval date of Feb. 28, 2018.

Previously, an advisory panel for the FDA voted 9-1 in favor of Rhopressa, concluding that its benefits outweigh its risks.